Limitations, agreements, and source contact

Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma · Source last updated 2026-03-27

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

true

point Of Contact

email

Ashlee_Sturtevant@dfci.harvard.edu

organization

Dana-Farber Cancer Institute

phone

(617) 632-4101

title

Senior Clinical Research Program Manager

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice